Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationSEDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) ...
The antiplatelet agent ticagrelor (Brilinta/Brilique, AstraZeneca) demonstrated bactericidal activity against antibiotic-resistant gram-positive bacteria that pose a threat to human health, including ...
When treating an infection, physicians may face a choice between using a bactericidal (bacteria-killing) drug, a bacteriostatic (bacteria-inhibiting) drug or a combination of the two. The solution is ...
Prospective randomized, open-label, multiple dose Phase 1 clinical trial This study was designed to evaluate the early and extended early bactericidal activity (EBA) of fluoroquinolone antibiotics ...
Cutting-edge tuberculosis therapy: Researchers test quabodepistat combinations, aiming for shorter, safer treatments to combat drug resistance and improve patient outcomes. Study: Safety, ...
When treating an infection, physicians may face a choice between using a bactericidal (bacteria-killing) drug, a bacteriostatic (bacteria-inhibiting) drug or a combination of the two. The solution is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results